Cytek Financial Statements From 2010 to 2024

CTKB Stock  USD 6.03  0.01  0.17%   
Cytek Biosciences financial statements provide useful quarterly and yearly information to potential Cytek Biosciences investors about the company's current and past financial position, as well as its overall management performance and changes in financial position over time. Historical trend examination of various income statement and balance sheet accounts found on Cytek Biosciences financial statements helps investors assess Cytek Biosciences' valuation, profitability, and current liquidity needs. Key fundamental drivers impacting Cytek Biosciences' valuation are summarized below:
Gross Profit
101 M
Profit Margin
(0.06)
Market Capitalization
760.1 M
Enterprise Value Revenue
3.0594
Revenue
200.8 M
We have found one hundred twenty available fundamental signals for Cytek Biosciences, which can be analyzed and compared to other ratios and to its rivals. All investors should make sure to validate all of Cytek Biosciences prevailing market performance against the performance between 2010 and 2024 to make sure the company can sustain itself down the road. The current year's Market Cap is expected to grow to about 2.2 B. The current year's Enterprise Value is expected to grow to about 1.9 B

Cytek Biosciences Total Revenue

139.86 Million

Check Cytek Biosciences financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among Cytek main balance sheet or income statement drivers, such as Net Interest Income of 5.5 M, Interest Income of 8 M or Depreciation And Amortization of 9.7 M, as well as many exotic indicators such as Price To Sales Ratio of 6.07, Dividend Yield of 0.0 or PTB Ratio of 3.3. Cytek financial statements analysis is a perfect complement when working with Cytek Biosciences Valuation or Volatility modules.
  
This module can also supplement Cytek Biosciences' financial leverage analysis and stock options assessment as well as various Cytek Biosciences Technical models . Check out the analysis of Cytek Biosciences Correlation against competitors.
For information on how to trade Cytek Stock refer to our How to Trade Cytek Stock guide.

Cytek Biosciences Balance Sheet

Current ValueLast YearHistorical Average 10 Year Trend
Total Assets389.7 M497.7 M186.3 M
Slightly volatile
Other Current Liabilities18.5 M24.9 M11.6 M
Slightly volatile
Total Current Liabilities40.7 M56.2 M27.7 M
Slightly volatile
Other Liabilities23.8 M34.9 M19.5 M
Slightly volatile
Property Plant And Equipment Net30.7 M29.3 M7.1 M
Slightly volatile
Current Deferred Revenue23.8 M22.7 MM
Slightly volatile
Accounts Payable3.6 MM2.7 M
Slightly volatile
Cash225.3 M167.6 M101.4 M
Slightly volatile
Non Current Assets Total110.9 M105.6 M23.4 M
Slightly volatile
Other Assets0.951.03.3 M
Slightly volatile
Cash And Short Term Investments256 M262.7 M112.7 M
Slightly volatile
Net Receivables37.5 M56.1 M24.5 M
Slightly volatile
Good Will8.2 M16.2 M3.3 M
Slightly volatile
Common Stock Total Equity83.9 K155.2 K48.9 K
Slightly volatile
Common Stock Shares Outstanding148.2 M135.3 M134.6 M
Slightly volatile
Liabilities And Stockholders Equity389.7 M497.7 M186.3 M
Slightly volatile
Non Current Liabilities Total67 M48.4 M87 M
Pretty Stable
Inventory40.2 M60.9 M25.9 M
Slightly volatile
Other Current Assets6.9 M12.3 M2.7 M
Slightly volatile
Total Liabilities96.6 M104.6 M113.9 M
Very volatile
Property Plant And Equipment Gross36.9 M35.2 MM
Slightly volatile
Total Current Assets342 M392.1 M167.1 M
Slightly volatile
Capital Stock95.9 K131 K48.1 K
Slightly volatile
Non Current Liabilities Other19.7 M18.9 M16 M
Slightly volatile
Net Working Capital301.3 M335.8 M139.4 M
Slightly volatile
Short Term Debt5.5 M5.6 MM
Pretty Stable
Intangible Assets24.2 M23.1 MM
Slightly volatile
Common Stock95.9 K131 K48.1 K
Slightly volatile
Property Plant Equipment16.5 M15.7 M4.3 M
Slightly volatile
Short and Long Term Debt Total19.8 M33.2 MM
Slightly volatile
Short and Long Term DebtM565 K2.2 M
Slightly volatile
Capital Surpluse476.6 M509.3 M434.2 M
Slightly volatile
Deferred Long Term Liabilities12.6 M15.1 M10.6 M
Slightly volatile
Long Term Debt1.6 M1.6 M2.2 M
Slightly volatile
Long Term Debt Total1.8 MM2.2 M
Slightly volatile

Cytek Biosciences Income Statement

Current ValueLast YearHistorical Average 10 Year Trend
Interest IncomeM7.6 M1.8 M
Slightly volatile
Depreciation And Amortization9.7 M9.2 MM
Slightly volatile
Interest Expense1.5 M2.1 M547.1 K
Slightly volatile
Selling General Administrative25.4 M44 M13.4 M
Slightly volatile
Selling And Marketing Expenses29.1 M49.1 M16.9 M
Slightly volatile
Total Revenue139.9 M193 M86.4 M
Slightly volatile
Gross Profit81.4 M109.4 M47.3 M
Slightly volatile
Other Operating Expenses140.4 M219.4 M85 M
Slightly volatile
Research Development27.7 M44.2 M15.6 M
Slightly volatile
Cost Of Revenue58.5 M83.6 M39.1 M
Slightly volatile
Total Operating Expenses81.9 M135.8 M45.8 M
Slightly volatile
Reconciled Depreciation9.1 M8.7 M1.9 M
Slightly volatile
Non Operating Income Net Other6.8 M6.5 M1.3 M
Slightly volatile

Cytek Biosciences Cash Flow Statement

Current ValueLast YearHistorical Average 10 Year Trend
Stock Based Compensation23.2 M22 M4.8 M
Slightly volatile
Begin Period Cash Flow199.3 M299.5 M100.8 M
Slightly volatile
Other Cashflows From Financing Activities2.7 M2.9 M1.1 M
Slightly volatile
Depreciation9.7 M9.2 MM
Slightly volatile
Capital Expenditures4.7 M4.8 M2.3 M
Slightly volatile
End Period Cash Flow226.2 M167.6 M101.9 M
Slightly volatile
Change To Netincome21 M20 M5.6 M
Slightly volatile
Dividends Paid922.4 K1.5 M340.5 K
Slightly volatile

Financial Ratios

Current ValueLast YearHistorical Average 10 Year Trend
Price To Sales Ratio6.076.392233.0535
Slightly volatile
Days Sales Outstanding77.26106104
Slightly volatile
Stock Based Compensation To Revenue0.120.11420.0293
Slightly volatile
EV To Sales5.415.695532.1963
Slightly volatile
Inventory Turnover1.661.37311.5661
Pretty Stable
Days Of Inventory On Hand195266233
Pretty Stable
Payables Turnover28.9527.568914.9612
Slightly volatile
Sales General And Administrative To Revenue0.130.22780.1331
Slightly volatile
Research And Ddevelopement To Revenue0.150.22870.1648
Slightly volatile
Cash Per Share1.381.94220.8061
Slightly volatile
Days Payables Outstanding26.2113.239527.2491
Slightly volatile
Intangibles To Total Assets0.08280.07890.022
Slightly volatile
Current Ratio6.526.97295.0838
Slightly volatile
Receivables Turnover4.293.43933.5421
Slightly volatile
Graham Number2.542.42291.1807
Slightly volatile
Revenue Per Share0.761.42670.6276
Slightly volatile
Interest Debt Per Share0.20.19050.0787
Slightly volatile
Debt To Assets0.0480.04760.0739
Slightly volatile
Operating Cycle272372337
Pretty Stable
Days Of Payables Outstanding26.2113.239527.2491
Slightly volatile
Quick Ratio5.615.67114.0772
Slightly volatile
Net Income Per E B T0.950.77331.0788
Pretty Stable
Cash Ratio4.492.98143.0267
Slightly volatile
Cash Conversion Cycle253359310
Very volatile
Days Of Inventory Outstanding195266233
Pretty Stable
Days Of Sales Outstanding77.26106104
Slightly volatile
Free Cash Flow Operating Cash Flow Ratio0.08170.0860.9092
Slightly volatile
Fixed Asset Turnover6.276.59742.6734
Slightly volatile
Debt Ratio0.0480.04760.0739
Slightly volatile
Price Sales Ratio6.076.392233.0535
Slightly volatile
Asset Turnover0.480.38780.6739
Slightly volatile
Gross Profit Margin0.460.56690.5181
Slightly volatile

Cytek Biosciences Valuation Data

Current ValueLast YearHistorical Average 10 Year Trend
Market Cap2.2 B1.2 B2.3 B
Slightly volatile
Enterprise Value1.9 B1.1 B2.2 B
Slightly volatile

Cytek Fundamental Market Drivers

Forward Price Earnings370.3704
Cash And Short Term Investments262.7 M

Cytek Upcoming Events

27th of February 2024
Upcoming Quarterly Report
View
14th of May 2024
Next Financial Report
View
31st of December 2023
Next Fiscal Quarter End
View
27th of February 2024
Next Fiscal Year End
View
30th of September 2023
Last Quarter Report
View
31st of December 2022
Last Financial Announcement
View

About Cytek Biosciences Financial Statements

There are typically three primary documents that fall into the category of financial statements. These documents include Cytek Biosciences income statement, its balance sheet, and the statement of cash flows. Cytek Biosciences investors use historical funamental indicators, such as Cytek Biosciences's revenue or net income, to determine how well the company is positioned to perform in the future. Although Cytek Biosciences investors may use each financial statement separately, they are all related. The changes in Cytek Biosciences's assets and liabilities, for example, are also reflected in the revenues and expenses that we see on Cytek Biosciences's income statement, which results in the company's gains or losses. Cash flows can provide more information regarding cash listed on a balance sheet, but not equivalent to net income shown on the income statement. We offer a historical overview of the basic patterns found on Cytek Biosciences Financial Statements. Understanding these patterns can help to make the right decision on long term investment in Cytek Biosciences. Please read more on our technical analysis and fundamental analysis pages.
Last ReportedProjected for Next Year
Current Deferred Revenue22.7 M23.8 M
Total Revenue193 M139.9 M
Cost Of Revenue83.6 M58.5 M
Stock Based Compensation To Revenue 0.11  0.12 
Sales General And Administrative To Revenue 0.23  0.13 
Research And Ddevelopement To Revenue 0.23  0.15 
Capex To Revenue(0.03)(0.03)
Revenue Per Share 1.43  0.76 
Ebit Per Revenue(0.14)(0.13)

Also Currently Popular

Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.
When determining whether Cytek Biosciences offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of Cytek Biosciences' financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Cytek Biosciences Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Cytek Biosciences Stock:
Check out the analysis of Cytek Biosciences Correlation against competitors.
For information on how to trade Cytek Stock refer to our How to Trade Cytek Stock guide.
You can also try the Idea Breakdown module to analyze constituents of all Macroaxis ideas. Macroaxis investment ideas are predefined, sector-focused investing themes.

Complementary Tools for Cytek Stock analysis

When running Cytek Biosciences' price analysis, check to measure Cytek Biosciences' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Cytek Biosciences is operating at the current time. Most of Cytek Biosciences' value examination focuses on studying past and present price action to predict the probability of Cytek Biosciences' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Cytek Biosciences' price. Additionally, you may evaluate how the addition of Cytek Biosciences to your portfolios can decrease your overall portfolio volatility.
Positions Ratings
Determine portfolio positions ratings based on digital equity recommendations. Macroaxis instant position ratings are based on combination of fundamental analysis and risk-adjusted market performance
Portfolio Diagnostics
Use generated alerts and portfolio events aggregator to diagnose current holdings
USA ETFs
Find actively traded Exchange Traded Funds (ETF) in USA
Money Managers
Screen money managers from public funds and ETFs managed around the world
Instant Ratings
Determine any equity ratings based on digital recommendations. Macroaxis instant equity ratings are based on combination of fundamental analysis and risk-adjusted market performance
FinTech Suite
Use AI to screen and filter profitable investment opportunities
Is Cytek Biosciences' industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Cytek Biosciences. If investors know Cytek will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Cytek Biosciences listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Quarterly Earnings Growth
0.658
Earnings Share
(0.09)
Revenue Per Share
1.497
Quarterly Revenue Growth
0.21
Return On Assets
(0.03)
The market value of Cytek Biosciences is measured differently than its book value, which is the value of Cytek that is recorded on the company's balance sheet. Investors also form their own opinion of Cytek Biosciences' value that differs from its market value or its book value, called intrinsic value, which is Cytek Biosciences' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Cytek Biosciences' market value can be influenced by many factors that don't directly affect Cytek Biosciences' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Cytek Biosciences' value and its price as these two are different measures arrived at by different means. Investors typically determine if Cytek Biosciences is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Cytek Biosciences' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.